Evidence map›Paper›PMID 38755998›Full record

ArticleThe Annals of pharmacotherapy2025

Buprenorphine in the Intensive Care Unit: Commentary on the Unanswered Questions.

David J Gagnon, Melody J Glenn, Aurora A Quaye, Brian L Erstad

Abstract read
In one paragraph

Article in The Annals of pharmacotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

David J GagnonDepartment of Pharmacy, Maine Medical Center, Portland, ME, USA.
Melody J GlennBanner-University Medical Center Tucson Base Hospital, Tucson, AZ, USA.
Aurora A QuayeTufts University School of Medicine, Boston, MA, USA.ORCID 0000-0002-7573-2164
Brian L ErstadUniversity of Arizona College of Pharmacy, Tucson, AZ, USA.ORCID 0000-0001-8909-9921

Funding

Telemedicine to Reduce Disparities in the Identification and Treatment of Neonatal EncephalopathyP20GM139745 · NIGMS · MAINEHEALTH · PI David B. Seder · 2021 to 2026
$19.2M
NIGMS NIH HHS P20 GM139745
6 · The paper itself

Abstract

The removal of the X-waiver in the Mainstreaming Addiction Treatment (MAT) Act of 2023 has substantial implications for buprenorphine prescribing as one of the options to treat opioid use disorder. The purpose of this commentary is to discuss the unanswered questions regarding buprenorphine in the intensive care unit (ICU) including how the passage of the MAT Act will affect ICU providers, which patients should receive buprenorphine, what is the most appropriate route of administration and dose of buprenorphine, what medications interact with buprenorphine, and how can transitions of care be optimized for these patients.

Indexed as

Analgesics, OpioidBuprenorphineIntensive Care UnitsNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersDrug InteractionsHumansAnalgesics, OpioidBuprenorphineNarcotic Antagonistsbuprenorphinecritical careopioid use disorder

Identifiers

PMID38755998
PMCPMC11660430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.